ELCC 2025 Post-Conference Intelligence

KRYSTAL7 1ST line treatment adagrasib + pembrolizumab metastatic KRASG12C NSCLC PDL1 ≥ 50% shows great results: ORR 59%, mPFS 27.7 m, mOS: NR. TRAEs leading to ADA dose reductions were ALT increase (11%), AST increase (7%) @Hospital_FJD @UAM_Madrid @OncoAlert @myESMO #ELCC2025 https://t.co/Zo2GoA7e2P

2.0K impressions

Ana I. Velázquez Mañana, MD, M

@anavmanana

Update from KRYSTAL-7 by @marinagarassino Adagrasib + Pembrolizumab in 1L KRAS G12C NSCLC w/ PD-L1 ≥ 50% 🔹 ORR 59% with mDOR 26.3 mo 🔹 mPFS 27.7 mo 🔹 mOS Not Reached w/ median f/u 24.9mo 🔹 11-13% w/ G3 LFTs elevations in the overall cohort #ELCC25 #LCSM #LungCancer https://t.co/B4XowjEHIF

1.9K impressions

Bartomeu Massuti

@bmassutis

Neoadjuvant chemoimmunotherapy is changing the field os respectability in Non Small Cell Lung Cancer and pathological complete response change the prognosis of patients by @MARIANOPROVENCI and @gecp_org at #ELCC2025 #lcsm @myESMO @OncoAlert https://t.co/OBqp3GcoB3

1.8K impressions

Julien Mazieres

@julienmazieres

Last brilliant and comprehensive talk by ⁦@RobertoFerrara_⁩ on resistance to immunotherapy covering multiple strategies to overcome complex mechanisms of resistance. Towards perfect days ?? #ELCC2025. What a session !!! 👏👏👏 https://t.co/A8Qbuxcx7E

1.6K impressions

Dr. Antonio Calles 🫁🚭

@tony_calles

@marinagarassino presents Phase 2 KRYSTAL-7: First-line adagrasib + pembrolizumab in 1st line KRASG12C-mut NSCLC & PD-L1>50% ✅ORR 59% ✅DoR 26.3 months ✅PFS 27.7 months ✅OS NR at 18 months ✅TRAEs overall manegable #ESMOAmbassadors #ELCC25 #LCSM @myESMO https://t.co/hASJoIib1I

1.5K impressions

IFCT lung

@ifctlung

4 highlights #ELCC25: - relapses in BR.31 trial by Virginie Westeel - long-term 4y OS atezolizumab #SCLC by @FalcheroLionel @nicogirardcurie, - immunotherapy de-escalation #DIAL by @BenjaminBesseMD - microenvironment #mesothelioma by Guillaume Tosato #LCS…

1.3K impressions

Dr Amol Akhade

@suyogcancer

Nice slide to show ADC targets in NSCLC. Lot of buzz and excitement in this field. Which one will make it big ? @myESMO #ELCC25 https://t.co/yJoplTMLJs

10.3K impressions

Jordi Remon

@jordiremon

Personalised approach at osimertinib PD with savolitinib and osimertinib in MET deregulated EGFRm NSCLC looks promising. Is it better than CT+Ami or ADC? Hwr, it is a chemofree strategy and other treatments could be applied later #ELCC25 https://t.co/PM8MSBFsFB

4.6K impressions

Noemi Reguart

@nreguart

ORCHARD Osi + Dato-DXd (6 mg/kg) in rEGFRm (n=33): mPFS 11.7 mo, ORR 36%, mDoR 20.5 mo. What’s going on in here???? Pooled TROPION Lung01/05 in rEGFRm: ORR 43%, mDoR 7, mPFS 5.8. Synergy????? . TROPION-LUNG14 (1L) and -LUNG15 (2L) ongoing #ESMOAmbassadors #ELCC25 @myESMO https://t.co/YkUPGVQXEe

3.7K impressions

Xiuning Le MD PhD

@lexiuning

A very successful #ELCC25 I presented Dato-DXd (4mg/kg vs 6mg/kg) with osimertinib in #EGFR refractory #NSCLC patients, from ORCHARD trial. mPFS 11.7 mon and ORR 36% in Dato-DXd 6mg/kg cohort. Improving upon what we have and explore new combinations. @lungoncdoc @MDAndersonNews https://t.co…

2.7K impressions

Julien Mazieres

@julienmazieres

Another brick in the wall of HER2 mut NSCLC. Promising efficacy of BAY in HER2 naive pts (ORR 70.5%) but also in pts treated with TDxD (ORR 35.3%). Diarrhea as the most frequent AE (almost all pts but no tt discontinuation). #ELCC25 @OncoAlert @nicogirardcurie https://t.co/Fc0KOS4Wvy

2.5K impressions

Patrick Forde

@fordepatrick

#ELCC25 Conclusion of Orchard study to chose DatoDxd 6mg/kg to move forward seems suspect to me. The 4mg/kg dose had much worse prognostic factors, slide below, I don’t think you can really make a comparison between them based on this cohort & 6mg looks worryingly toxic. #lcsm https://t.co/pr7XfzmQrF

2.5K impressions

Stephen V Liu, MD

@stephenvliu

#ELCC25 program includes OS updates from MARIPOSA & LAURA in #EGFR NSCLC, adagrasib + pembrolizumab in #KRAS G12C, & final analysis from KEYNOTE 799 of pembrolizumab + chemoradiation in stage III NSCLC. Educational program highlights include AI session with Dr. @PrelajArsela https://t.co/fbz…

10.4K impressions

Dr. Antonio Calles 🫁🚭

@tony_calles

💊 Daraxonrasib (RMC-6236) oral, RAS(ON), multi-selective, tricomplex inhibitor of GTP-bound mutant and wild-type RAS in KRAS G12X mutant NSCLC ✅ORR = 38%, ✅DOR = 15.5 months ✅PFS = 9.8 m ✅OS = 17.7 m ⚠️Skin prophylaxis required. ✳️ 200 mg was selected for evaluation in https://t.co/3DmPgXKcWA

8.4K impressions

Jarushka Naidoo

@drjnaidoo

#ELCC25 Mini Orals Ph II KROCUS trial: 1L fulzerasib + cetuximab in KRAS G12C+ NSCLC by @margamajem - ORR 68.9% (by investigator 80%) - DCR 100% - mPFS 12.5m - very tolerable tox, activity in STK11+, KEAP1+ @myESMO @OncoAlert #LCSM https://t.co/2pfDFoYWpY

3.2K impressions

Dr Amol Akhade

@suyogcancer

Can we improve outcomes of KRAS mutated advanced NSCLC? What's the new data #ELCC2025 @myESMO check the slide to compare the results of adagrasib plus pembrolizumab and Fulzerasib plus Cetuximab with current SOC . Money 💰 slide 🙂 https://t.co/rV0eRtbo7N

3.2K impressions

Dr Amol Akhade

@suyogcancer

Daraxonrasib . New first in class pan RAS inhibitor. Compared with Adagrasib and Sotorasib in NSCLC. @myESMO #ELCC2025 https://t.co/h6sILcFVrk

2.2K impressions

Ana I. Velázquez Mañana, MD, M

@anavmanana

Update from KRYSTAL-7 by @marinagarassino Adagrasib + Pembrolizumab in 1L KRAS G12C NSCLC w/ PD-L1 ≥ 50% 🔹 ORR 59% with mDOR 26.3 mo 🔹 mPFS 27.7 mo 🔹 mOS Not Reached w/ median f/u 24.9mo 🔹 11-13% w/ G3 LFTs elevations in the overall cohort #ELCC25 #LCSM #LungCancer https://t.co/B4XowjEHIF

1.9K impressions

Grupo Español de Cáncer de Pul

@gecp_org

👉🏼Poster @gecp_org en #ELCC2025 🗣️ “PROGNOSTIC VALUE OF MINIMAL RESIDUAL DISEASE IN THE NADIM II TRIAL.” 📌El estudio #NADIM sigue aportando información sobre #cancerdepulmon en estadios tempranos @Serna_Blasco #LungCancer #Oncologia #NADIM…

2.9K impressions

Dr Deridre Kelly

@deirdre24643831

#ELCC2025 @AlixPanabieres Liquid bx = dynamic real-time insight into tumour biology Captures ctDNA, CTCs, exosomes, immune + microbial signals High-value for MRD, monitoring, prognosis Context critical Functional biomarker ≠ tissue gold standard. @myESMO @OncoAlert #LCSM https://t.co/xCKVpHNymD

870 impressions

Dr. Iván R. González

@dr_ivanoncologo

🧬 At #ELCC2025, researchers highlighted how minimal residual disease (MRD) detection and cfDNA analysis can enhance tumour assessment beyond traditional RECIST criteria. 💊 🔬 These methods offer early relapse detection and personalized treatment insights, marking an exciting https://t.co/UOR5sn0A5C

511 impressions

Santhosh Ambika

@renohemonc

@SuyogCancer @myESMO Pts without MRD clearace may benefit from extending adj Osi.. https://t.co/0nNnsom0qi https://t.co/TS9THW0FXD

228 impressions

sevinç ballı

@sevincballi

Dr. Catherine Alix-Panabieres , great session ✨ MRD detection in lung cancer ? Escalation or de-escalation treatment ? Treatment resistance detection ? @isliquidbiopsy @myESMO #ELCC2025 https://t.co/B6fQi3KmgY

150 impressions

Umberto Malapelle

@umbertomalapel1

Thinking about liquid biopsy at #ELCC25. #ESMOAmbassador @myESMO @IASLC https://t.co/EqEnWsq9Dn

1.4K impressions

Dr Deridre Kelly

@deirdre24643831

#ELCC2025 @AlixPanabieres Liquid bx = dynamic real-time insight into tumour biology Captures ctDNA, CTCs, exosomes, immune + microbial signals High-value for MRD, monitoring, prognosis Context critical Functional biomarker ≠ tissue gold standard. @myESMO @OncoAlert #LCSM https://t.co/xCKVpHNymD

870 impressions

Dr. Iván R. González

@dr_ivanoncologo

🧬 At #ELCC2025, researchers highlighted how minimal residual disease (MRD) detection and cfDNA analysis can enhance tumour assessment beyond traditional RECIST criteria. 💊 🔬 These methods offer early relapse detection and personalized treatment insights, marking an exciting https://t.co/UOR5sn0A5C

511 impressions

Jarushka Naidoo

@drjnaidoo

#ELCC25 ADCs in NSCLC Exceptional talk by @g_mountzios on ADCs in oncogene+ NSCLC, highlighting: - compelling data in this subset of pts targeting EGFR, HER2 etc) - favourable brain activity - future constructs: e.g. pro-body drug conjugates @myESMO @OncoAlert #LCSM https://t.co/TDg4EhKJJC

3.7K impressions

Julien Mazieres

@julienmazieres

Another brick in the wall of HER2 mut NSCLC. Promising efficacy of BAY in HER2 naive pts (ORR 70.5%) but also in pts treated with TDxD (ORR 35.3%). Diarrhea as the most frequent AE (almost all pts but no tt discontinuation). #ELCC25 @OncoAlert @nicogirardcurie https://t.co/Fc0KOS4Wvy

2.5K impressions

Ana I. Velázquez Mañana, MD, M

@anavmanana

SOHO-01: BAY 2927088 in previously treated HER2 mut. NSCLC Cohort D: HER2-targeted therapy naive 🔹 ORR 70.5% 🔹 mDoR 8.7 mo Cohort E: previously tx with HER2 ADCs 🔹 ORR 35.3% 🔹 mDoR 9.5 mo AEs: diarrhea, rash, nausea, paronychia & others #LCSM #ELCC25 #ELCC2025 https://t.co/lobLj6Mdow

1.2K impressions

Giannis Mountzios

@g_mountzios

Best way to start #ELCC25 with @peters_solange dissecting the current landscape of bispesifics and T-cell engagers, with emphasis on double TAA targeting , immune bispecifics, TAA/CD16 NK -engagers and TAA/CD3 T-cell engagers #ESMOAmbassadors @myESMO #LCSM https://t.co/axqY4fXoXa

4.3K impressions

Roberto Ferrara

@robertoferrara_

Overcoming resistance to PD-1/PD-L1 inhibitors still major challange after 15 years! LAG3 inhibition failed..and as a bispecific. Need to work on biomarkers #ELCC2025 https://t.co/JQe6RIDIGK

651 impressions

Jarushka Naidoo

@drjnaidoo

#ELCC25 AI in lung cancer Um… so one of the best talks at ELCC, is from a radiologist? What? Florian Fintelmann @Harvard outlines the promise of AI in lung imaging: - radiomics - AI model developmt & implementation - sybil/lung cancer screening @myESMO @Oncoalert #LCSM https://t.co/CSn5Eee…

3.2K impressions

Jarushka Naidoo

@drjnaidoo

#ELCC25 AI in lung cancer Superb overview of AI in - pathology - large language models - integration of these data to answer the big biomarker questions in oncology A must-watch by @ERC_Research-funded AI star @jnkath @myESMO @Oncoalert #LCSM https://t.co/v9U8RXK0fl

1.6K impressions

ELCC 2025

Who moved the needle at ELCC 2025

Top trials discussed

What KOLs were talking about

Trials discussed at ELCC 2025

The 10 tweets that defined ELCC 2025